摘要
目的对去势抵抗性前列腺癌个体化药物治疗的临床效果进行分析。方法40例去势抵抗性前列腺癌患者,利用随机分组研究法分为对比组与研究组,各20例。对比组患者使用常规多西他赛联合泼尼松治疗,研究组患者使用阿比特龙联合泼尼松治疗。对比两组患者治疗效果;治疗前后血浆总前列腺特异抗原(tPSA)、睾酮水平;治疗前后最大尿流率(MFR)、残余尿量(PVR)和Karnofsky功能状态评分标准(KPS)评分;治疗后不良反应发生情况。结果研究组患者治疗总有效率90.00%明显高于对比组的60.00%,差异具有统计学意义(P<0.05)。治疗后,研究组患者血浆tPSA(13.44±3.71)ng/ml、睾酮(16.65±0.25)nmol/L均明显优于对比组的(20.19±3.84)ng/ml、(12.38±0.47)nmol/L,差异具有统计学意义(P<0.05)。治疗后,研究组患者MFR(14.40±0.85)ml/s、PVR(24.16±1.93)ml和KPS评分(68.60±5.26)分均优于对比组的(11.29±0.93)ml/s、(29.97±1.84)ml、(63.34±5.87)分,差异有统计学意义(P<0.05)。研究组患者治疗后不良反应发生率25.00%低于对比组的60.00%,差异有统计学意义(P<0.05)。结论去势抵抗性前列腺癌个体化药物治疗的临床效果显著,患者接受治疗后血清指标良好,故值得在临床中广泛使用。
Objective To analyze the clinical effect of personalized drug therapy for castration-resistant prostate cancer.Methods A total of 40 patients with castration-resistant prostate cancer were randomly divided into control group and research group,with 20 cases in each group.The control group was treated by docetaxel combined with prednisone,and the research group was treated by abiraterone combined with prednisone.The therapeutic effect,total prostate specific antigen(tPSA),testosterone level,maximum flow rate(MFR),post-void residual(PVR),Karnofsky functional criteria before and after treatment,and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment 90.00%of the research group was obviously higher than that of the control group 60.00%,and the difference was statistically significant(P<0.05).After treatment,the plasma tPSA(13.44±3.71)ng/ml,testosterone(16.65±0.25)nmol/L of the research group were obviously better than those of the control group(20.19±3.84)ng/ml and(12.38±0.47)nmol/L,and the difference was statistically significant(P<0.05).After treatment,MFR(14.40±0.85)ml/s,PVR(24.16±1.93)ml and KPS score(68.60±5.26)points of the research group were better than those of the control group(11.29±0.93)ml/s,(29.97±1.84)ml and(63.34±5.87)points,and the difference was statistically significant(P<0.05).After treatment,the incidence of adverse reactions 25.00%of the research group was lower than that of the control group 60.00%,and the difference was statistically significant(P<0.05).Conclusion Personalized drug therapy shows remarkable clinical effect for castration-resistant prostate cancer,and the serum indicators of patients after treatment are good,so it is worthy of wide application in clinic.
作者
关文峰
何京伟
冯能卓
梁其炎
黄亦欣
覃文超
GUAN Wen-feng;HE Jing-wei;FENG Neng-zhuo(Second Department of Urology,Yangjiang People’s Hospital,Yangjiang 529500,China)
出处
《中国实用医药》
2020年第15期4-7,共4页
China Practical Medicine
关键词
去势抵抗性前列腺癌
个体化
化疗
Castration-resistant prostate cancer
Personalized drug therapy
Chemotherapy
